Edward Tenthoff
Stock Analyst at Piper Sandler
(3.7)
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ALNY Alnylam Pharmaceutic... | Maintains: Overweight | 304 449 | 469.31 | -4.33% | 8 | Aug 1, 2025 | |
NXTC NextCure | Maintains: Overweight | 36 15 | 5.49 | 173.22% | 5 | Jul 15, 2025 | |
INO Inovio Pharmaceutica... | Initiates Coverage On: Overweight | 5 | 2.64 | 89.39% | 1 | Jul 9, 2025 | |
CRSP CRISPR Therapeutics | Reiterates: Overweight | 105 105 | 51.81 | 102.66% | 7 | Jun 27, 2025 | |
STRO Sutro Biopharma | Upgrades: Overweight | 2 2 | 0.91 | 119.78% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 7 | 1.84 | 280.43% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 9 | 6.99 | 28.76% | 4 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 16 12 | 10.15 | 18.23% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 24 14 | 7.83 | 78.8% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 4 2 | 0.51 | 292.16% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 53 48 | 13.28 | 261.45% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 15 24 | 15.56 | 54.24% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 78 78 | 33.47 | 133.04% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 20 30 | 8.36 | 258.85% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 62 45 | 28.89 | 55.76% | 10 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 115 69 | 24.31 | 183.83% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 4 | n/a | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 1 | 0.88 | 13.64% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 104 65 | 10.53 | 517.28% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | 2.79 | 545.16% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 35 | 6.33 | 452.92% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 20 20 | 4.13 | 384.26% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 3 3 | 1.41 | 112.77% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 13 5 | n/a | n/a | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 8 3 | 0.76 | 294.74% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 16 16 | 4.8 | 233.33% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 4 6 | 1 | 500% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 150 150 | 1.71 | 8671.93% | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 120 80 | 0.6 | 13233.33% | 5 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 5 | 1.71 | 192.4% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 39 56 | 43.48 | 28.79% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 8 10 | 9.5 | 5.26% | 3 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 5 2 | n/a | n/a | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 13 | 12.5 | 0% | 2 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 7 | n/a | n/a | 2 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 224 248 | 14.14 | 1653.89% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 1 | n/a | n/a | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 13 20 | 1.9 | 952.63% | 5 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 5 | 1.88 | 165.96% | 3 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 90 | 3.39 | 2554.87% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 2 | n/a | n/a | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 140 180 | 17.59 | 923.31% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 37 44 | 15.81 | 178.3% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 160 60 | n/a | n/a | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 76 37 | 7 | 428.57% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 175 100 | 12.01 | 732.64% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 2246640 651200 | n/a | n/a | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 250 354 | 762.89 | -53.6% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 135 | 1.52 | 8781.58% | 2 | Sep 20, 2021 |